Class / Patent application number | Description | Number of patent applications / Date published |
514455000 | Chalcogen bonded directly to ring carbon of the hetero ring | 87 |
20080287527 | Pharmaceuticals for treating or preventing oral diseases - The present invention discloses hydroxy-morusin, a method of extracting hydroxy-morusin, as well as various uses in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses. | 11-20-2008 |
20080300300 | Use of alpha-mangostin as a mosquito larvicide - Methods of killing mosquito larvae and controlling an adult mosquito population by using α-mangostin, 3,6,8-yrihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one, or a salt, solute, hydrate or solvate thereof. Mosquito larvae are killed by contacting a lethal dose of α-mangostin with mosquito larvae. Adult mosquito populations are controlled by treating a mosquito larvae population with a lethal dose of α-mangostin. | 12-04-2008 |
20090023802 | Benzochromene Derivatives - The present invention relates to benzochromene derivatives of the formula I | 01-22-2009 |
20090054516 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME - A pharmaceutical composition having a cytotoxic effect to a cancer cell and a method for the same are provided. The pharmaceutical composition comprises a flavonoid compound having at least one of the following formulas: | 02-26-2009 |
20090062377 | ANTI-CANCER COMBINATIONS - The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations. | 03-05-2009 |
20090062378 | Nutraceutical Mangosteen Composition - Nutraceutical compositions derived from the fruit of the | 03-05-2009 |
20090076128 | DEUTERIUM-ENRICHED TOPIRAMATE - The present application describes deuterium-enriched topiramate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090137662 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS - This invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, this invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating one or more symptoms produced by the chronic consumption of a substance of abuse or to mitigate one or more physiological and/or behavioral symptoms associated with cessation of chronic consumption of a substance of abuse. In certain embodiments, the methods involve administering to the mammal an effective amount of an adenosine receptor antagonist; and an effective amount of a dopamine receptor antagonist; where the effective amount of the adenosine receptor antagonist is lower than the effective amount of an adenosine receptor antagonist administered without said dopamine receptor antagonist. | 05-28-2009 |
20090143462 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same - Described herein are Δ | 06-04-2009 |
20090170927 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM - The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. | 07-02-2009 |
20090176870 | TGF-BETA MODULATORS AND METHODS FOR USING THE SAME - The present invention provides a method of modulating TGF-β activity in a subject. Methods of the present invention comprise administering to the subject an effective amount of a compound of the formula: | 07-09-2009 |
20090221693 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention refers to compounds of the general formulae I as defined above, preferably α-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function and endurance. Other fields of use are eating disorders such as bulimia and anorexia nervosa, use for accelerating wound healing, and/or use for the treatment/prevention of bone disorders such as osteoporosis and osteopenia. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of preventing and/or treating the above mentioned disorders/diseases, as well as to methods of maintaining the healthy state and/or improving the baseline conditions in mammals including humans and to the compounds of the formula I themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the prevention and/or treatment of such disorders/diseases as mentioned above. | 09-03-2009 |
20090233997 | COMPOSITION FOR PROMOTING SYNTHESIS OF COLLAGEN, AND COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN COMPRISING THE SAME - The present invention relates to a composition for promoting collagen synthesis and a composition for external application to skin which includes the collagen synthesis promoting composition. The collagen synthesis promoting composition includes, as an effective component, at least one selected from the group consisting of compounds represented as: wherein R is hydrogen, a methoxy group, or a 3-methyl-2-butenyl group. The composition for external application to skin includes at least one collagen synthesis promoting component selected from the group consisting of compounds represented by above. | 09-17-2009 |
20090239942 | Topiramate Compositions and Methods of Making and Using the Same - The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same. | 09-24-2009 |
20090247620 | Benzochromene Derivatives for Use in Liquid Crystal Media and as Therapeutic Active Substances - The present invention relates to benzochromene derivatives of the formula I | 10-01-2009 |
20090292012 | Therapeutic Agent - A therapeutic agent or prophylactic agent for a disease requiring an anti-foaming action for a cell and/or an inhibitory action for acyl-CoA cholesterol acyltransferase in treatment or prevention, characterized in that the therapeutic agent or prophylactic agent comprises as an effective ingredient a processed product derived from | 11-26-2009 |
20090298930 | Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol - Methods for making trans-(−)-Δ | 12-03-2009 |
20090298931 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation. | 12-03-2009 |
20090306197 | Substituted Chromanol Derivatives and Their Use - The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders. | 12-10-2009 |
20090312406 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): | 12-17-2009 |
20100016419 | ANTIBACTERIAL COMPOSITION - The object of the present invention is to provide an antibacterial composition which has an improved antibacterial effect and a wider antibacterial spectrum than conventional antibacterial agents and which is highly safe. | 01-21-2010 |
20100022632 | USE CERTAIN DITERPENE COMPOUNDS IN THE TREATMENT OF ANDROGEN RECEPTOR-ASSOCIATED DISEASES - The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses methods of treating androgen receptor-associated diseases by administering the disclosed diterpenes. | 01-28-2010 |
20100076069 | FORSKOLIN DOSING REGIMEN IN OPEN ANGLE GLAUCOMA AND PATIENT COMPLIANCE METHODS THEREOF - Disclosed is an optimal dosing regimen for forskolin to ensure the most optimal pharmacokinetic/pharmacodynamic responses desired in the therapeutic management of open angle glaucoma. The optimal dosing regimen involves the ocular application of 2% forskolin solubilized using randomly-methylated beta-cyclodextrins one drop once a day to patients requiring therapy for open angle glaucoma. Also disclosed are methods of promoting patient compliance, in particular geriatric and pediatric patient compliance during the therapeutic management of glaucoma using an optimal dosing regimen for forskolin to ensure the best pharmacokinetic/pharmacodynamic effects, devoid of systemic side-effects encountered with the currently used beta-blockers or prostaglandins. | 03-25-2010 |
20100076070 | Forskolin Compositions and Methods For Administration - An administration method is provided, in which a composition comprising a forskolin 1α,9α-carbonate compound is administered to a human subject. According to an embodiment, the forskolin 1α,9α-carbonate compound has a skeletal structure of 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one. A carbonyl group links the 1-position hydroxy oxygen and the 9-position hydroxy oxygen to one another for forming a carbonate ester ring. Hydrogen is appended to the 6-position hydroxy oxygen. A hydrogen or an acetyl group is appended to the 7-position hydroxy oxygen. | 03-25-2010 |
20100087518 | DELTA 9 - TETRAHYDROCANNABINOL PROCESSING - The present invention provides a process for handling Δ9-THC, which comprises preparing a solution of Δ9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of Δ9-THC in the solvent and solid preparations of Δ9-THC. | 04-08-2010 |
20100093843 | NOVEL NUTRACEUTICAL AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF CARTILAGE DEGRADATION OR CARTILAGE DAMAGE IN JOINTS - The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R | 04-15-2010 |
20100099754 | 5,6-DIMETHYL XANTHONE-4-ACETIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME - A method of preparation of 5,6-dimethylxanthone-4-acetic acid (DMXAA) and derivatives thereof. The derivatives are represented by formula (I), wherein R represents totally 1 to 2 substitutes at 1, 2, 3, 7, and 8 position selected from a lower alkyl, halogen, CF | 04-22-2010 |
20100105764 | USE - There is provided a method for the manufacture of a medicament for the treatment of cancer comprising a compound capable of inhibiting a steroid sulphatase enzyme (E.C.3.1.6.2), wherein the cancer is of a type, in which the cancer cells overexpress aromatase enzyme. | 04-29-2010 |
20100105765 | Combination Therapy For Effecting Weight Loss And Treating Obesity - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 04-29-2010 |
20100113583 | COMBINATION THERAPIES FOR THE TREATMENT OF OBESITY - Described are pharmaceutical compositions comprising bupropion, metformin, topiramate, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and topiramate. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both. | 05-06-2010 |
20100144855 | APPLICATION OF SEDOISOPROSAN FOR PREPARATION OF MEDICINE FOR TREATMENT OF HUMAN HBeAg POSITIVE CHRONIC HEPATITIS B - The present invention disclosed the application of sedoisoprosan for preparation of medicine for therapy on human HBeAg positive chronic hepatitis B. Results of the clinical trials indicated that sedoisoprosan could effectively inhibit hepatitis B virus, the anti-virus effect is enhanced as the dose is increased and the incidence of adverse events is low. Thus, sedoisoprosan is safe and effective for therapy on human HBeAg positive chronic hepatitis B. | 06-10-2010 |
20100286254 | CRYSTALLINE FORMS OF DMXAA SODIUM SALT - The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents. | 11-11-2010 |
20100298422 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME - Novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and a method for preparing the same. | 11-25-2010 |
20100298423 | NUTRACEUTICAL COMPOSITION FROM GARCINIA MANGOSTANA - Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from | 11-25-2010 |
20110021618 | METHODS OF TREATING FIBROTIC DISORDERS - Described herein are compositions and methods for preventing and/or treating fibrotic disorders employing one or more benzo[c]chromen-6-one derivatives. | 01-27-2011 |
20110054013 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula: | 03-03-2011 |
20110092584 | THERAPEUTIC USE OF QUINONOID DERIVATIVES OF CANNABINOIDS - The present invention relates to cannabinoic quinone compounds, and especially to their medical use. In particular five cannabinoic quinones, designated HU-331, HU-336, HU-345, HU-395 and HU-396 are herein described as active agents in pharmaceutical compositions. Said compounds and compositions thereof are intended for the treatment of inflammatory, infectious, auto-immune and particularly hyperproliferative disorders. Thus, the compounds of the invention may be used as anti-tumor agents, or for the treatment of cancer. Furthermore, three of these compounds, HU-345, HU-395 and HU-396, are novel cannabinoic quinones and thus are also claimed herein. | 04-21-2011 |
20110092585 | IMMUNOMODULATORY PHARMACEUTICAL COMPOSITION AND A PROCESS FOR PREPARATION THEREOF - The present invention provides a novel pharmaceutical composition consisting of a combination of three coumarinolignoids of formula 1, 2 and 3 isolated from the seeds of the plant | 04-21-2011 |
20110105599 | THERAPEUTIC OR PREVENTIVE AGENTS FOR ISCHEMIC NEUROPATHY - Therapeutic or preventive agents for ischemic nerve injury containing as the active ingredient compounds represented by the general formula [2]: | 05-05-2011 |
20110118343 | Antitumoral Macrolides - Antitumoral compounds of general formula I: | 05-19-2011 |
20110144193 | Pharmaceutical Composition Comprising Cinchonains Ia And Ib, Process For Preparing An Epimeric Mixture Of Cinchonains Ia And Ib, Use And Method For Reverting/Combating Ventricular Fibrillation - The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, essentially in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. | 06-16-2011 |
20110144194 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Compounds of general formula (I) and (II) in which R | 06-16-2011 |
20110160298 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF BONE LOSS - A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn. | 06-30-2011 |
20110166217 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF BONE LOSS - A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn. | 07-07-2011 |
20110201678 | Xanthenone-4-Acetic Acid Derivatives - This invention relates to novel compounds that are xanthenone-4-acetic acid derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel xanthenone-4-acetic acid derivatives that are derivatives of AS 1404. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a vascular disrupting agent, such as AS 1404. | 08-18-2011 |
20110218239 | Use of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antiviral Agent - The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses. | 09-08-2011 |
20110263694 | Use of Xanthone Derivatives as a Medicament for Cancer - The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma. | 10-27-2011 |
20110263695 | NFAT Signal Inhibitor and Hair-Growing Agent - An NFAT signal inhibitor and the like are provided. | 10-27-2011 |
20120115940 | USE OF TOTAL COUMARINS OF CNIDIUM FRUIT IN PREPARING MEDICAMENTS FOR TREATING PSORIASIS - A pharmaceutic composition for treating psoriasis. Ii has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition. | 05-10-2012 |
20120184604 | COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING COLFORSIN DAROPATE - The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases comprising colforsin daropate, and more particularly, the present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases such as bone fracture and osteoporosis, which inhibits osteoclast differentiation and bone resorption caused by osteoclasts and promotes osteoblast differentiation and the activity of osteoblasts, and a health functional food composition comprising colforsin daropate. | 07-19-2012 |
20120264819 | Therapeutic Uses of Urolithins - The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject. | 10-18-2012 |
20120277297 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors - The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marrnesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7 -methoxycoumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions possess a high degree of acetylcholinesterase inhibitory (AChE) property. | 11-01-2012 |
20120302630 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof - Na/K-ATPase/Src ligands, assays and uses thereof are disclosed. | 11-29-2012 |
20130012576 | Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same - The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a | 01-10-2013 |
20130102659 | Salvinorin Compositions and Uses Thereof - The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusion. The invention further relates to treating various diseases or disorders. | 04-25-2013 |
20130210906 | COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF FOR TREATING CANCER - The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases. | 08-15-2013 |
20130217761 | Pharmaceutical Composition Comprising Cinchonains Ia and Ib, Process For Preparing An Epimeric Mixture of Cinchonains Ia and Ib, Use and Method for Reverting/Combating Ventricular Fibrillation - The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. The present invention further relates to methods for the synthesis of an epimeric mixture of the chemical substances cinchonain Ia and Ib. The present invention also relates to the use of these chemical substances in reverting/combating ventricular fibrillation and/or in protecting against ventricular fibrillation. A pharmaceutical composition will be used for administering these chemical substances in human beings and animals. | 08-22-2013 |
20130274323 | METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS - Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): | 10-17-2013 |
20130310448 | METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION - This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to Inhibit functions of ATR and FANCD2 on DNA replication, damage checkpoint, and repair; therefore, this composition can improve the cancer sensitivity and poor prognosis to DNA-damaging therapeutics. | 11-21-2013 |
20130324596 | SPIROKETALS - The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests. | 12-05-2013 |
20140018415 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 01-16-2014 |
20140018416 | THERAPEUTIC AGENT FOR CORNEAL SENSORY NERVE DAMAGE CONTAINING SEMAPHORIN INHIBITOR AS ACTIVE INGREDIENT - A compound represented by formula (1), or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves: | 01-16-2014 |
20140031419 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof - The present disclosure relates to methods of inhibiting the ATPase activity of Na/K-ATPase without stimulating the receptor function, methods of blocking Na/K-ATPase interaction with Src, methods of inhibiting cell growth, and methods of abolishing ouabain-provoked signaling transduction in the heart of a subject, which includes providing an effective amount of at least one hydroxyl xanthone derivative. | 01-30-2014 |
20140080903 | APPLICATION OF ALPHA-MANGOSTIN IN PREPARATION OF MEDICAMENTS FOR ALZHEIMER'S DISEASE - The invention discloses a new use of α-Mangostin in medicine, which is application of α-Mangostin in preparation of medicaments for Alzheimer's disease. Under the new working concentration, α-Mangostin showed the capability to inhibit the aggregation and deposition of Aβ. Moreover, it displayed the neuroprotective effect against neurotoxicity caused by Aβ oligomer, which maintained normal morphology of mammalian neuron cells, enhanced their normal physiological function, and realized the intervention in pathological process of Alzheimer's disease. The invention provided a new approach to treat Alzheimer's disease. | 03-20-2014 |
20140100270 | RADIATION COUNTERMEASURE AGENTS - Methods and compositions for reducing radiation damage in a subject with analog or derivative of benzo[c]chromen-6-one. | 04-10-2014 |
20140187623 | Escalating Dosing Regimen For Effecting Weight Loss And Treating Obesity - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 07-03-2014 |
20140200265 | USAGE OF 1,3,5,7-TETRAHYDROXY-8-ISOPRENYLXANTHONE FOR TREATING INFLAMMATION - This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. | 07-17-2014 |
20140221470 | COMPOUND FOR INHIBITING GLUTATHIONE S-TRANSFERASE OMEGA 1 ACTIVITY, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, AND METHOD FOR SYNTHESIZING THE SAME - A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: | 08-07-2014 |
20140221471 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS - Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives. | 08-07-2014 |
20140303243 | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism - Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided. | 10-09-2014 |
20140315992 | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism - Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided. | 10-23-2014 |
20140350093 | METHODS OF TREATING OR PREVENTING INSULIN RESISTANCE AND ASSOCIATED DISEASES AND CONDITIONS - Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R | 11-27-2014 |
20150038568 | USE OF TOTAL COUMARINS OF CNIDIUM FRUIT IN PREPARING MEDICAMENTS FOR TREATING PSORIASIS - A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by weight of the active component, which accounts for 5-35% by weight of the overall pharmaceutic composition. | 02-05-2015 |
20150038569 | Anti-cervical Cancer Compound and Method of Use Thereof - Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor. | 02-05-2015 |
20150057343 | AGONISTS OF THE AhR RECEPTOR PATHWAY HAVING SEBOSUPPRESSIVE ACTIVITY AND A METHOD FOR IDENTIFYING SAID AGONISTS - The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions. | 02-26-2015 |
20150099801 | Methods of Preventing Progression to Type 2 Diabetes Mellitus - The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome. | 04-09-2015 |
20150148409 | NOVEL DAIDZEIN ANALOGS AS TREATMENT FOR CANCER - Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth. | 05-28-2015 |
20150366840 | SALVINORIN COMPOSITIONS AND USES THEREOF - The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation. For example, salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment. | 12-24-2015 |
20150366841 | Pd-Ib for Treating Inflammation - The present invention provides a compound, namely (+)-3′-Angeloyloxy-4′-keto-3′, 4′-dihydroseselin (Pd-Ib) derived from | 12-24-2015 |
20160000752 | METHOD FOR INCREASING MUSCLE GROWTH BY BLOCKING SIRTUIN ACTIVITY - Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective. | 01-07-2016 |
20160002194 | 1 -(DIMETHYLAMINO)ETHYL-SUBSTITUTED 6H-BENZO[C]CHROMEN-6-ONES AGAINST SENILE DEMENTIA - This invention relates to novel (±)1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions. | 01-07-2016 |
20160002195 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS - The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders. | 01-07-2016 |
20160045472 | UROLITHIN B FOR MUSCLE GROWTH - A composition includes a sufficient amount of urolithin B, or a derivative thereof, for increasing muscle cell size. | 02-18-2016 |
20160185744 | COMPOUND FOR INHIBITING SYK ACTIVITY - A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity, | 06-30-2016 |
20160185745 | ANALOGS OF VINAXANTHONE AND XANTHOFULVIN, METHODS OF SYNTHESIS, AND METHODS OF TREATMENTS THEREOF - The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof. | 06-30-2016 |
20180021268 | WEIGHT LOSS/REDUCTION OF VISCERAL FAT COMPOUND AND METHOD OF EXTRACTION AND PREPARATION | 01-25-2018 |
20220133690 | Pharmaceutical Composition for Treatment of Bone-Related Disease - The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. | 05-05-2022 |